Wild options for Geovax Labs investors

Geovax Labs Price to Book Value is fairly stable at the moment as compared to the past year. Geovax Labs reported Price to Book Value of 1.35 in 2020. Price to Sales Ratio is likely to rise to 2.63 in 2021, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (3 M) in 2021. While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to break down Geovax Labs. We will analyze why it could be a much better year for Geovax Labs shareholders. This post is to show some fundamental factors affecting Geovax Labs' products and services. I will also show how it may impact the investing outlook for the company in May.
Published over a year ago
View all stories for GeoVax Labs | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Michael Smolkin

About 5.0% of Geovax Labs shares are owned by institutional investors. Insiders ownership of Geovax Labs refers to the amount of Geovax Labs equity owned by Geovax officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Geovax, including its current ownership diagnostics.
The performance of GeoVax Labs in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence GeoVax Labs' stock prices. When investing in GeoVax Labs, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, GeoVax Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as GeoVax Labs carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.

How important is GeoVax Labs's Liquidity

GeoVax Labs financial leverage refers to using borrowed capital as a funding source to finance GeoVax Labs ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. GeoVax Labs financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to GeoVax Labs' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of GeoVax Labs' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between GeoVax Labs's total debt and its cash.

What do experts say about GeoVax?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
Analysis Consensus

Another angle On GeoVax Labs

The market capitalization of Geovax Labs is $28.61 Million. Geovax Labs retains 8.32 (percent) if its outstanding shares held by insiders and 8.32 (percent) owned by outside corporations . Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Ownership Breakdown

Retail Investors
87.15%
Insiders
8.32%
Retail Investors87.15
Insiders8.32
Institutions4.53

Are Geovax Labs technical indicators showing a recoup?

The total risk alpha is down to -1.1 as of today. Geovax Labs is displaying above-average volatility over the selected time horizon. Investors should scrutinize Geovax Labs independently to ensure intended market timing strategies are aligned with expectations about Geovax Labs volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Geovax Labs' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Geovax Labs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

While some other entities in the biotechnology industry are either recovering or due for a correction, Geovax Labs may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 9th of April 2021, we see that Geovax Labs hyperactively responds to market trends. The company is undervalued with very low probability of distress within the next 24 months. Our final 30 days 'Buy-vs-Sell' recommendation on the company is Cautious Hold.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of GeoVax Labs. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com